Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells

JAK2-V617F plays a key role in the pathogenesis of myeloproliferative neoplasm. However, its inhibitor ruxolitinib has shown limited clinical efficacies because of the ruxolitinib-persistent proliferation of JAK2-V617F-positive cells. We here demonstrate that the USP9X inhibitor WP1130 or EOAI340214...

Descripción completa

Detalles Bibliográficos
Autores principales: Akiyama, Hiroki, Umezawa, Yoshihiro, Watanabe, Daisuke, Okada, Keigo, Ishida, Shinya, Nogami, Ayako, Miura, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072561/
https://www.ncbi.nlm.nih.gov/pubmed/32050632
http://dx.doi.org/10.3390/cancers12020406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072561/
https://www.ncbi.nlm.nih.gov/pubmed/32050632
http://dx.doi.org/10.3390/cancers12020406

Ejemplares similares